Home
Scholarly Works
Benefit from exemestane (EXE) as extended adjuvant...
Conference

Benefit from exemestane (EXE) as extended adjuvant therapy after 5 years of tamoxifen (TAM): intent-to-treat analysis of NSABP B-33.

Authors

Mamounas E; Jeong J-H; Wickerham L; Smith R; Geyer C; Ganz P; Land S; Hutchins L; Eisen A; Ingle J

Volume

100

Pagination

pp. S22-S22

Publisher

SPRINGER

Publication Date

January 1, 2006

Name of conference

29th Annual San Antonio Breast Cancer Symposium

Conference place

TX, San Antonio

Conference start date

December 14, 2006

Conference end date

December 17, 2006

Conference proceedings

BREAST CANCER RESEARCH AND TREATMENT

ISSN

0167-6806

Contact the Experts team